Sygnamap Inc.

San Antonio, TX Doing business as Sygnamap Inc.

UEI
FH41QG5NZ2Y6
CAGE
8H8G6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Subcontinent Asian (Asian-Indian) American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
7733 Louis Pasteur Dr #301, San Antonio, TX 78229, USA
Website
sygnamap.com
Founded
2020
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

About Sygnamap Inc.

Sygnamap Inc. is a minority-owned, for-profit corporate entity located in San Antonio, Texas, registered in SAM.gov and specializing in computational platforms for advanced medical research and drug development technologies. The company focuses on developing innovative computational approaches that leverage spatial metabolomics, mass spectrometry imaging, and artificial intelligence/machine learning techniques to analyze complex biological data. Sygnamap's core technological expertise centers on creating computational platforms that can quantify and normalize molecular data to support precision medicine and drug discovery efforts.

Through its federal grant awards, Sygnamap Inc. has consistently received funding from prestigious federal agencies including the National Institute of Standards and Technology (NIST), National Institute of General Medical Sciences, National Science Foundation, and National Institute of Diabetes and Digestive and Kidney Diseases. The company's grant-funded projects predominantly focus on developing advanced computational platforms for analyzing spatial metabolomics data, with specific emphasis on disease pathway identification, particularly in kidney disease, diabetic nephropathy, and broader medical research domains. Notable projects include developing MSI-DEEPPATH, a computational platform for quantifying spatially distinct metabolite abundancies, creating technologies to infer causative disease pathways, and designing innovative point-of-care devices for measuring chiral metabolites. These projects typically involve developing computational models, establishing calibration standards, and creating technologies that can convert semi-quantitative mass spectrometry data into rigorous, quantitative results to support biotech and pharmaceutical research and development efforts.

Quick answers

What is Sygnamap Inc.'s UEI?

Sygnamap Inc.'s Unique Entity ID (UEI) in SAM.gov is FH41QG5NZ2Y6.

What is Sygnamap Inc.'s CAGE code?

Sygnamap Inc.'s CAGE code is 8H8G6.

What is Sygnamap Inc.'s primary NAICS code?

Sygnamap Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Sygnamap Inc. located?

Sygnamap Inc.'s physical address in SAM.gov is 7733 Louis Pasteur Dr #301, San Antonio, TX 78229, USA.

Is Sygnamap Inc. registered in SAM.gov?

Yes. Sygnamap Inc.'s SAM.gov registration is active through May 26, 2027.

What is Sygnamap Inc.'s most recent federal award?

Sygnamap Inc.'s most recent federal grant award is Purpose: traceable reference standards is becoming an indispensable tool for pharmaceutical companies to identify… (70NANB24H198), from National Institute of Standards and Technology, on October 1, 2024.

On GovTribe

See Sygnamap Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors